Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Clinical trial NCT04566393 · AVAILABLE

Trial details

NCT number: NCT04566393
Sponsor: xCures
Status: AVAILABLE
Study type: EXPANDED_ACCESS

Pancreatic Cancer Small Bowel Cancer Colorectal Cancer Melanoma Non Small Cell Lung Cancer Thyroid Cancer Bladder Cancer Head and Neck Cancer Gastric Cancer Esophageal Cancer Cholangiocarcinoma Ovarian Cancer

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.